Liquidia Technologies Inc. To Present New Data Supporting The Role Of Particle Size And Shape In Vaccine Development
8/13/2014 7:59:21 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia Technologies today announced that it will present new data demonstrating the influence of tunable PRINT® (Particle Replication In Non-Wetting Templates) particle characteristics on the immune response as a component of vaccine development. Results from this preclinical study will be presented at the 9th Annual ImVacS, The Immunotherapies and Vaccine Summit, being held August 11-14, 2014 in Boston, Massachusetts. The ImVacS Summit brings together a global audience of vaccine researchers and developers of cancer immunotherapies for five focused meetings that explore the frontiers of immunology as the basis for patient treatment.
Help employers find you! Check out all the jobs and post your resume.
comments powered by